Bank of Montreal Can Has $878,000 Stock Position in Jasper Therapeutics, Inc. $JSPR

Bank of Montreal Can grew its stake in Jasper Therapeutics, Inc. (NASDAQ:JSPR) by 120.4% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 158,133 shares of the company’s stock after purchasing an additional 86,393 shares during the period. Bank of Montreal Can owned approximately 1.05% of Jasper Therapeutics worth $878,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also modified their holdings of the company. T. Rowe Price Investment Management Inc. boosted its stake in Jasper Therapeutics by 755.3% in the 1st quarter. T. Rowe Price Investment Management Inc. now owns 702,757 shares of the company’s stock valued at $3,022,000 after buying an additional 620,592 shares in the last quarter. Nuveen LLC acquired a new position in Jasper Therapeutics during the first quarter worth $440,000. Kingdon Capital Management L.L.C. lifted its holdings in shares of Jasper Therapeutics by 9.6% during the first quarter. Kingdon Capital Management L.L.C. now owns 490,000 shares of the company’s stock valued at $2,107,000 after acquiring an additional 43,000 shares during the period. Corton Capital Inc. acquired a new stake in shares of Jasper Therapeutics in the 1st quarter valued at $113,000. Finally, Goldman Sachs Group Inc. grew its holdings in shares of Jasper Therapeutics by 11.2% in the 1st quarter. Goldman Sachs Group Inc. now owns 233,758 shares of the company’s stock worth $1,005,000 after purchasing an additional 23,453 shares during the last quarter. Institutional investors own 79.85% of the company’s stock.

Insider Transactions at Jasper Therapeutics

In other news, Director Thomas G. Wiggans acquired 41,000 shares of the company’s stock in a transaction on Monday, September 22nd. The stock was purchased at an average cost of $2.43 per share, with a total value of $99,630.00. Following the acquisition, the director owned 41,000 shares of the company’s stock, valued at $99,630. This trade represents a ∞ increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Judith Anne Shizuru bought 41,000 shares of the business’s stock in a transaction on Monday, September 22nd. The shares were acquired at an average price of $2.43 per share, for a total transaction of $99,630.00. Following the completion of the transaction, the director owned 156,901 shares in the company, valued at approximately $381,269.43. This trade represents a 35.38% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Over the last three months, insiders acquired 143,000 shares of company stock worth $347,490. 4.60% of the stock is owned by insiders.

Jasper Therapeutics Price Performance

Shares of Jasper Therapeutics stock opened at $1.68 on Friday. The firm has a 50 day simple moving average of $2.31 and a 200 day simple moving average of $3.56. Jasper Therapeutics, Inc. has a fifty-two week low of $1.56 and a fifty-two week high of $26.05. The firm has a market cap of $27.30 million, a P/E ratio of -0.28 and a beta of 2.83.

Jasper Therapeutics (NASDAQ:JSPR) last announced its quarterly earnings data on Monday, November 10th. The company reported ($1.13) EPS for the quarter, missing analysts’ consensus estimates of ($1.01) by ($0.12). On average, sell-side analysts expect that Jasper Therapeutics, Inc. will post -4.47 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on JSPR shares. UBS Group cut their price target on shares of Jasper Therapeutics from $29.00 to $25.00 and set a “buy” rating for the company in a report on Friday, August 15th. JMP Securities dropped their price objective on shares of Jasper Therapeutics from $12.00 to $6.00 and set a “market outperform” rating for the company in a report on Monday, September 22nd. Evercore ISI reduced their target price on Jasper Therapeutics from $20.00 to $14.00 and set an “outperform” rating on the stock in a report on Monday, September 22nd. BTIG Research decreased their price target on Jasper Therapeutics from $20.00 to $7.00 and set a “buy” rating on the stock in a research report on Monday, September 22nd. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Jasper Therapeutics in a research report on Wednesday, October 8th. Six research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Jasper Therapeutics currently has an average rating of “Hold” and an average target price of $25.63.

Jasper Therapeutics Company Profile

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.